Related Experiment Video

Updated: Jul 7, 2026

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates
09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research

Halina Ostrowska1

  • 1Department of Biology, Medical University of Bialystok, Bialystok, Poland. osthal@amb.edu.pl

Cellular & Molecular Biology Letters
|March 4, 2008
PubMed

Insights

The ubiquitin-proteasome system regulates key cell processes. Inhibitors targeting this system show promise for treating cancer and inflammatory diseases.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • The ubiquitin-proteasome system (UPS) degrades intracellular proteins controlling crucial cellular functions like cell cycle, apoptosis, and signal transduction.
  • Dysregulation of the UPS is implicated in the pathogenesis of numerous human diseases.
  • The ubiquitin-conjugating system and the 20S proteasome are validated targets for therapeutic intervention.

Purpose of the Study:

  • To review small molecule inhibitors and modulators of the ubiquitin-proteasome system.
  • To elucidate their mechanisms of action.
  • To discuss their therapeutic potential in oncology and inflammatory diseases.

Main Methods:

  • Literature review of small molecule inhibitors and modulators of the UPS.
  • Analysis of their mechanisms of action.
  • Evaluation of their therapeutic relevance.

Main Results:

  • Several small molecule inhibitors and modulators targeting the UPS have been identified.
  • These agents exhibit diverse modes of action, including proteasome inhibition and interference with ubiquitination pathways.
  • Promising therapeutic applications in cancer and inflammatory conditions are emerging.

Conclusions:

  • Small molecule targeting of the ubiquitin-proteasome system represents a significant area for drug discovery.
  • Inhibitors and modulators of the UPS hold considerable therapeutic potential for treating cancer and inflammatory diseases.
  • Further research into these agents could lead to novel treatment strategies.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.